Article Type
Changed
Thu, 08/26/2021 - 15:50
Display Headline
COVID-19 vaccines: New candidates & answers to commonly asked questions

REFERENCES

  1. CDC. COVID-19 vaccination. Accessed February 22, 2021.
  2. CDC. COVID data tracker. Accessed February 22, 2021.
  3. Oliver SE, Gargano JW, Marin M, et al. The Advisory Committee on Immunization Practices’ interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine—United States, December 2020. MMWR Morbid Mortal Wkly Rep. 2020;69:1922-1924. Accessed February 22, 2021.
  4. Oliver SE, Gargano JW, Marin M, et al. The Advisory Committee on Immunization Practices’ interim recommendation for use of Moderna COVID-19 vaccine—United States, December 2020. MMWR Morbid Mortal Wkly Rep. 2021;69:1653-1656. Accessed February 22, 2021.
  5. Gee J, Marquez P, Su J, et al. First month of COVID-19 vaccine safety monitoring—United States, December 14, 2020–January 13, 2021. MMWR Morbid Mortal Wkly Rep. ePub: February 19, 2021. Accessed February 22, 2021.
  6. CDC COVID-19 Response Team; Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine—United States, December 21, 2020–January 10, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:125-129. Accessed February 25, 2021.
Author and Disclosure Information

Doug Campos-Outcalt, MD, MPA, is a clinical professor at the University of Arizona College of Medicine, a senior lecturer with the University of Arizona College of Public Health, and a member of the US Community Preventive Services Task Force. He’s also an assistant editor at The Journal of Family Practice.

The speaker reported no potential conflict of interest relevant to this audiocast.

Issue
The Journal of Family Practice - 70(2)
Publications
Topics
Page Number
audio
Sections
Author and Disclosure Information

Doug Campos-Outcalt, MD, MPA, is a clinical professor at the University of Arizona College of Medicine, a senior lecturer with the University of Arizona College of Public Health, and a member of the US Community Preventive Services Task Force. He’s also an assistant editor at The Journal of Family Practice.

The speaker reported no potential conflict of interest relevant to this audiocast.

Author and Disclosure Information

Doug Campos-Outcalt, MD, MPA, is a clinical professor at the University of Arizona College of Medicine, a senior lecturer with the University of Arizona College of Public Health, and a member of the US Community Preventive Services Task Force. He’s also an assistant editor at The Journal of Family Practice.

The speaker reported no potential conflict of interest relevant to this audiocast.

REFERENCES

  1. CDC. COVID-19 vaccination. Accessed February 22, 2021.
  2. CDC. COVID data tracker. Accessed February 22, 2021.
  3. Oliver SE, Gargano JW, Marin M, et al. The Advisory Committee on Immunization Practices’ interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine—United States, December 2020. MMWR Morbid Mortal Wkly Rep. 2020;69:1922-1924. Accessed February 22, 2021.
  4. Oliver SE, Gargano JW, Marin M, et al. The Advisory Committee on Immunization Practices’ interim recommendation for use of Moderna COVID-19 vaccine—United States, December 2020. MMWR Morbid Mortal Wkly Rep. 2021;69:1653-1656. Accessed February 22, 2021.
  5. Gee J, Marquez P, Su J, et al. First month of COVID-19 vaccine safety monitoring—United States, December 14, 2020–January 13, 2021. MMWR Morbid Mortal Wkly Rep. ePub: February 19, 2021. Accessed February 22, 2021.
  6. CDC COVID-19 Response Team; Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine—United States, December 21, 2020–January 10, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:125-129. Accessed February 25, 2021.

REFERENCES

  1. CDC. COVID-19 vaccination. Accessed February 22, 2021.
  2. CDC. COVID data tracker. Accessed February 22, 2021.
  3. Oliver SE, Gargano JW, Marin M, et al. The Advisory Committee on Immunization Practices’ interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine—United States, December 2020. MMWR Morbid Mortal Wkly Rep. 2020;69:1922-1924. Accessed February 22, 2021.
  4. Oliver SE, Gargano JW, Marin M, et al. The Advisory Committee on Immunization Practices’ interim recommendation for use of Moderna COVID-19 vaccine—United States, December 2020. MMWR Morbid Mortal Wkly Rep. 2021;69:1653-1656. Accessed February 22, 2021.
  5. Gee J, Marquez P, Su J, et al. First month of COVID-19 vaccine safety monitoring—United States, December 14, 2020–January 13, 2021. MMWR Morbid Mortal Wkly Rep. ePub: February 19, 2021. Accessed February 22, 2021.
  6. CDC COVID-19 Response Team; Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine—United States, December 21, 2020–January 10, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:125-129. Accessed February 25, 2021.
Issue
The Journal of Family Practice - 70(2)
Issue
The Journal of Family Practice - 70(2)
Page Number
audio
Page Number
audio
Publications
Publications
Topics
Article Type
Display Headline
COVID-19 vaccines: New candidates & answers to commonly asked questions
Display Headline
COVID-19 vaccines: New candidates & answers to commonly asked questions
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Mon, 02/22/2021 - 13:45
Un-Gate On Date
Mon, 02/22/2021 - 13:45
Use ProPublica
CFC Schedule Remove Status
Mon, 02/22/2021 - 13:45
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content